Pharmaceuticals & Diagnostics

  • Adenovir Pharma

    Epidemic keratoconjunctivitis, EKC, is a serious and highly contagious viral eye infection, which lacks effective treatment. EKC can be found all over the world, but is more common in heavily populated countries in Asia, with approximately one million cases of EKC per year in Japan alone. Adenovir Pharma is developing new solutions for treatment of certain infectious diseases affecting the eyes. The company was founded by researchers at the department of Virology, Umeå University, Sweden and the P.U.L.S. AB network. Adenovir Pharma´s aim is to develop a topical pharmaceutical product against EKC, based their unique proprietary technology; which forces certain viruses to aggregate and inhibit them from binding to and infecting human corneal cells. The product acts outside the human cells, and there is low risk for development of viral resistance.

    Read more

  • APL AB

    APL is a leading Scandinavian contract manufacturer within the Life science sector with resources for development, manufacturing and analysis of pharmaceuticals. APL is also one of Europe's largest manufacturers of extemporaneous pharmaceuticals. APL has an annual turnover of about 150 M€ and 550 employees at four production facilities in Sweden (Umeå, Stockholm, Göteborg and Malmö) and also at preparation units at hospitals.

    Read more

  • Asarina Pharma AB

    Asarina Pharma (former Umecrine Mood) was founded in 2006 as a subsidiary to Umecrine AB. The business concept of the company is to develop treatments for the negative mental and physical symptoms in Premenstrual Dysphoric Disorder (PMDD) and Premenstrual Syndrome (PMS) caused by endogenous CNS-active steroids derived from the corpus luteum of the ovary. The company offers a unique and novel treatment principle based on inhibition of GABA-steroid action. The portfolio of the company includes a number of newly discovered lead compounds and a drug candidate that is under clinical investigation.

    Read more

  • Betagenon AB

    Betagenon works with research and development of new drugs to treat type 2 diabetes and other diseases linked to obesity and sedentary. We focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat chronic energy balance disorders diseases in metabolically challenged elderly and/or obese individuals. Drugs that activate AMPK are also expected to have beneficial effects on metabolic and cardiovascular diseases and on certain cancers. We also have a close collaboration with Umeå University and the ground breaking research has in recent years led to international attention. The goal is to develop drugs that can prevent and/or cure diabetes and other diseases caused by our western lifestyle.

    Read more

  • Follitech AB

    Follitech was founded in 2010 and has a strong collaboration with a group of scientists at the Department of Medical Chemistry and Biophysics at Umeå University. The company aims to address and treat infertility associated with POF (premature ovarian failure). POF is a condition that affects 1 in 100 women, and in these women the ovaries prematurely stop their monthly production of mature eggs before they reach 40 years of age. The condition is also associated with a reduction of estrogen which causes classical symptoms and health problems associated with menopause in these young women, but in particular, infertility due to the lack of mature eggs. At the moment, there are no treatment for POF, but the company have make discoveries and see potential in finding a treatment in the years to come.

    Read more

  • Helicure

    Helicure was founded in 2005 and develops vaccines to cure peptic ulcer disease and to protect against gastric cancer, based on eradication of "bad" Helicobacter pylori infections. In the western world, up to 50% of the population is infected with Heliobacter pylori and the proportion considerably larger in Asia. By using proprietary attachment proteins from Heliobacter pylori as immunization agents, combined with immune stimulating adjuvants, oral or nasal vaccines will be created.

    Read more

  • Lipum AB

    Lipum develops an anti-inflammatory drug with first-in-class potential and we aim for better quality of life for the millions suffering from chronic inflammatory diseases, also children. Distressed by pain, disability, and comorbidities many have to leave a normal working life in advance. We intend to increase their quality of life and decrease the considerable health care and societal costs.

    Read more

  • Nordic Biomarker

    Nordic Biomarker develops and manufactures advanced reagents designed to fit the various coagulation instruments available in the hospital laboratories. We serve selected OEM-clients to make their hemostasis product portfolio complete, but we also offer some of our reagents as complete CE-marked Nordic branded kits. Furthermore, our reagents for measuring fibrin D-dimer are used to diagnose thrombosis in many hospital laboratories around the world. Recently a reagent for measuring the free form of Protein S was introduced to the market. We are open to new ideas, and invest heavily in research and development to increase future product offering

    Read more

  • Omnio AB

    Development of health care products and contract research in the field of molecular biology and protein chemistry.

    Read more

  • Omnio Healer AB

    Omnio Healer develops treatment of various types inflammatory diseases especially diabetic wounds, with novel drug candidates based on a series of conceptual breakthroughs in inflammation research. We have obtained patent protection covering the use of plasminogen, plasmin and their derivatives, for promoting wound healing. The drug product for the lead indication diabetic wounds is formulated as a solution for local injections.

    Read more

  • QureTech Bio AB

    QureTech Bio AB is a drug development company formed in 2010 to commercialize world-leading research from groups based at Umeå University, Sweden, and Washington University, St Louis. We specialize in creating drugs for chlamydia and other pathogenic diseases. Today, antibiotic resistance is a major problem in the world and we are creating a new class of anti-infective agents known as virulence blockers, which have the unique ability to prevent the disease-causing properties of certain pathogenic bacteria without disrupting the normal bacterial flora. Thereby, we reduce the risk of resistance development.

    Read more

  • Strålen AB

    Strålen is a privately owned research and development company based in Umeå. We work in close collaboration with medical research and clinical doctors at the University hospital in Umeå.

    Read more

  • UmanDiagnostics AB

    Uman Diagnostics is specialized in early detection of diseases in the brain. We are involved in establishing a new diagnostic immunochemical test for fast and accurate determination of neurological and traumatic injuries. The NF-light assay is an enzymatic two-side immunoassay for quantitative determinations of NF-light in human body fluids. We have a close collaboration with research groups at many departments at Umeå University and the company also collaborates with a number of Swedish and foreign biotech companies.

    Read more

  • Umecrine AB

    Umecrine was founded in 2000 by leading scientists at Umeå University. We are active in research and development of pharmaceutical agents to reduce negative mental and physical CNS-related conditions caused by endogenous sex and stress hormones on the brain. This is a unique and novel treatment principle based on antagonizing the action of GABA-A (GABA-A modulating steroid antagonists, GAMSA) receptor modulating steroids.

    Read more

  • Umecrine Cognition AB

    Umecrine Cognition was founded as a subsidiary to Umecrine AB. Umecrine Cognition is developing pharmaceuticals against neurological disorders in the central nervous system, CNS that are caused by endogenous CNS-active steroids (GABA-steroids). Furthermore, is company active in development and commercialization of novel therapeutics to treat Hepatic Encephalopathy (HE) in patients with liver disease, a growing area with high unmet medical need. HE is a neurocognitive and neuropsychiatric complication, characterized by impaired cognitive and motor functions with symptoms ranging from disorientation through coma. We are developing pharmaceuticals to treat acute life-threatening HE and long-term maintenance in minimal HE caused by endogenous GABA-steroids.

    Read more